Recap Of Thursday’s Biotech Catalysts – End Of the Day Summary
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Intellia Therapeutics’ (NASDAQ:NTLA) lead asset NTLA-2002,…
FDA Advisory Committee Meeting Scheduled For October 28, 2022 To Review Y-mAbs’ Refiling For Omburtamab
The Oncologic Drugs Advisory Committee (ODAC) of the U.S.
Recap Of Tuesday’s Biotech Catalysts – End Of the Day Summary
Amgen (NASDAQ:AMGN) announced top-line results from the global Phase 3 CodeBreaK 200 trial evaluating once daily oral LUMAKRAS (sotorasib)…
Y-mAbs Gets Regulatory Approval In Israel For Neuroblastoma Candidate
The Israeli Ministry of Health has approved Y-mAbs Therapeutics’ (NASDAQ: YMAB) lead drug DANYELZA in combination with granulocyte-macrophage colony-stimulating factor for pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.
Y-mAbs’ Announces Clearance of IND For GD2-SADA
NEW YORK, July 12, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB) a commercial-stage biopharmaceutical company focused on the development and
BMO Capital Initiates Coverage On Y-mAbs Therapeutics with Outperform Rating, Announces Price Target of $27
BMO Capital analyst Etzer Darout initiates coverage on Y-mAbs Therapeutics (NASDAQ:YMAB) with a Outperform rating and announces Price Target of $27.
Y-mAbs Therapeutics Earnings Perspective: Return On Capital Employed
According to data from Benzinga Pro, during Q1, Y-mAbs Therapeutics's (NASDAQ:YMAB) reported sales totaled $10.49 million. Despite a 23.92% increase in earnings, the company posted a loss of $28.07 million.
Y-mAbs Announces FDA Acceptance Of Biologics License Application For OMBLASTYS For Treatment Of Neuroblastoma For Priority Review
Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic
Y-mAbs Announces Naxitamab Chemoimmunotherapy Investigational Trial For High-Risk Neuroblastoma Meets Primary Endpoint
Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic